Business Context and Reporting Period
This Form 8-K is a current report filed by Manhattan Pharmaceuticals, Inc. (Note: Request metadata lists "TG THERAPEUTICS, INC." but the filing text identifies the registrant as Manhattan Pharmaceuticals, Inc.) dated October 28, 2009. The report discloses unregistered sales of equity securities and a settlement of an arbitration proceeding.
Key Financial Metrics and Transactions
- Debt Issuance: Sold a 12% Original Issue Discount Senior Subordinated Convertible Debenture with a stated value of $400,000.
- Warrant Issuance: Issued a warrant to purchase 2,222,222 shares of common stock at an exercise price of $0.11 per share.
- Placement Agent Compensation: Issued warrants to purchase an aggregate of 222,222 shares of common stock to National Securities Corporation and designees.
- Existing Debt: The new Debenture is subordinated to outstanding 12% Senior Secured Promissory Notes totaling $1,725,000.
- Settlement Liability: Agreed to pay $200,000 cash and issue a $250,000 interest-free promissory note to settle an arbitration award.
Material Changes and Events
Capital Structure Change: The company increased its debt and potential equity dilution through the issuance of the convertible debenture and associated warrants. The debenture is convertible at an initial price of $0.09 per share, with provisions for adjustment based on future financing.
Legal Settlement: The company resolved an arbitration with Swiss Pharma Contract LTD regarding an obesity trial. While the original award was approximately $646,000, the settlement reduced the obligation to $200,000 in cash and a $250,000 note, totaling $450,000 in consideration.
Guidance, Risks, and Contingencies
Forward-Looking Statements: The filing contains forward-looking statements regarding future events and expectations, which are subject to risks and uncertainties. Actual results may differ materially.
Risk Factors: The company directs investors to the "Risk Factors" section of its Annual Report on Form 10-K for the fiscal year ended December 31, 2008, for a comprehensive list of risks.
Contingencies: The settlement with Swiss Pharma is a resolved contingency, but the issuance of the promissory note creates a future cash flow obligation.
Investor Verification Checklist
- Verify the exact conversion terms and anti-dilution adjustments for the $400,000 Debenture.
- Confirm the total number of shares outstanding post-issuance of the 2,222,222 warrant shares and 222,222 placement agent shares.
- Review the company's cash position to assess the ability to pay the $200,000 immediate settlement amount and service the $1,725,000 senior notes.
- Check for any effective registration statements required to allow the transfer of the restricted securities issued in this transaction.